Cybin Inc.
Industry
- Biotechnology
- Pharmaceuticals
- Drug Delivery
Other Names/Subsidiaries
- Adelia Therapeutics
- Cybin IRL
- Nature Journey
- Serenity Life Sciences
- Small Pharma
Latest on Cybin Inc.
Lykos Therapeutics is not taking the rejection of midomafetamine lying down. The company said late on 9 August that the product, a version of the illicit drug MDMA for the treatment of post-traumatic
Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte
Cybin Inc. will initiate a Phase III program for its deuterated psilocybin analog CYB003 for major depressive disorder (MDD) after demonstrating encouraging efficacy in Phase II studies and aligning
The US FDA will face some crucial tests for its nascent approach to regulation of psychedelic drug candidates in the coming year, headlined by an 11 August 2024 user fee goal for the first psychedelic